Arthneeti
TM

Themis Medicare Ltd

Q4 FY24Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q4 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book

Q4 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹118
Market cap₹1.1K Cr
Updated24 Sept 2026
Read3 min read

Based on Themis Medicare Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q4 FY24 Net Revenue: Rs. Quarterly EBITDA (Q4 FY24): Rs.

From Themis Medicare Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY24 Net Revenue: Rs. 97.82 Cr, up 22.11% YoY from Rs. 80.10 Cr in Q4 FY23 (Page 8)
  • Hospital Business grew over 21% YoY for FY24 (Page 8)
  • FY24 Net Revenue: Rs. 381.76 Cr, up 7.74% YoY from Rs. 354.32 Cr in FY23 (Page 9)
  • EBITDA margin for Q4 FY24 declined by 358 bps YoY due to production halts and investment (Page 8)
  • No explicit volume figures disclosed

2 more points management made on revenue & sales performance

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly detail specific capex amounts, capacity expansions, or new plant/project initiatives with corresponding timelines or current statuses. However, the following related points can be inferred: - Themis Medicare has three manufacturing facilities: formulations (Haridwar), synthetic APIs (Hyderabad and Vapi) with state-of-the-art, vertically integrated capabilities. - The company plans to develop in-house APIs for both consumption and commercial production as part of its hospital business strategy. - Continued investment in R&D is shown with increasing spend from Rs. 4.59 Cr. (FY18-19) to around Rs. 13.69-14.25 Cr. in FY22-24.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation of Themis Medicare Ltd. does not explicitly mention or report any figures or details related to: - Order book - Order inflow - Pending orders No specific data or commentary on these aspects is provided anywhere in the 19-page presentation. The focus is primarily on financial performance, business segments, R&D, strategic outlook, and management commentary without reference to current order status or backlog.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bharat Parenterals Ltd (Q4 FY24)

    For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key investor presentation takeaways from B

  • Fermenta Biotech Ltd (Q4 FY24)

    Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key investor presentation takeaways from Fermenta Biotech Ltd's Q4 FY24 investor

  • Amrutanjan Health Care Ltd (Q4 FY24)

    OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q4 FY24 investor presentation — and

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Themis Medicare Ltd Q4 FY24 results?

Q4 FY24 Net Revenue: Rs. Quarterly EBITDA (Q4 FY24): Rs.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Is Themis Medicare Ltd planning capital expenditure?

The investor presentation does not explicitly detail specific capex amounts, capacity expansions, or new plant/project initiatives with corresponding timelines or current statuses.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.